{"id":1028375,"date":"2026-08-27T23:36:16","date_gmt":"2026-08-27T23:36:16","guid":{"rendered":"https:\/\/www.europesays.com\/us\/1028375\/"},"modified":"2026-08-27T23:36:16","modified_gmt":"2026-08-27T23:36:16","slug":"newly-approved-drug-is-a-game-changer-for-stage-4-pancreatic-cancer-patients-central-oregon-daily","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/1028375\/","title":{"rendered":"Newly approved drug is a "game changer" for Stage 4 pancreatic cancer patients – Central Oregon Daily"},"content":{"rendered":"
    \n
  1. Newly approved drug is a “game changer” for Stage 4 pancreatic cancer patients<\/a>  Central Oregon Daily<\/li>\n
  2. FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease<\/a>  WSJ<\/li>\n
  3. FDA Approves RASONQUE\u2122 (daraxonrasib)<\/a>  Pancreatic Cancer Action Network<\/li>\n
  4. FDA Approves RevMed\u2019s Breakthrough Pill for Pancreatic Cancer<\/a>  Bloomberg<\/li>\n
  5. New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many<\/a>  The New York Times<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"Newly approved drug is a “game changer” for Stage 4 pancreatic cancer patients  Central Oregon Daily FDA Approves Drug…\n","protected":false},"author":3,"featured_media":1028376,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[235,371828,210,1060,411226,1190,9226,67,132,68],"class_list":["post-1028375","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-cancer","tag-daraxonrasib","tag-health","tag-medication","tag-pancreatic","tag-therapy","tag-treatment","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/117170103175233037","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/1028375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=1028375"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/1028375\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/1028376"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=1028375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=1028375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=1028375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}